Xeris Biopharma Holdings, Inc. XERS Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $111.75M+91.2% | $111.04M+55.0% | $91.6M+54.6% | $59.29M+2.9% | $58.44M-6.8% | ||
| $56.3M+21.5% | $51.05M+26.3% | $53.75M+30.7% | $53.05M+25.0% | $46.33M+23.8% | ||
| $74.23M+40.9% | $68.67M+42.5% | $67.46M+49.5% | $67.28M+56.6% | $52.69M+28.9% | ||
| $9.4M+55.8% | $9.55M+28.1% | $11.21M+56.9% | $5.96M-18.9% | $6.03M-21.0% | ||
| $251.68M+53.9% | $240.31M+43.3% | $224.02M+37.6% | $185.58M+8.9% | $163.49M-5.6% | ||
| $5.03M-4.3% | $4.95M-11.1% | $4.95M-11.9% | $5.28M-9.4% | $5.26M-9.0% | ||
| $21.95M-2.6% | $22.11M-2.4% | $22.26M-2.2% | $22.4M-2.0% | $22.53M-2.2% | ||
| $22.86M0.0% | $22.86M0.0% | $22.86M0.0% | $22.86M0.0% | $22.86M0.0% | ||
| $85.37M-11.3% | $88.08M-11.0% | $90.79M-10.7% | $93.5M-10.4% | $96.21M-10.1% | ||
| $5.12M+0.5% | $5.22M-3.5% | $5.32M-2.3% | $5.06M-7.9% | $5.1M+10.5% | ||
| $392.01M+24.3% | $383.53M+18.7% | $370.19M+15.3% | $334.69M+0.9% | $315.45M-6.3% | ||
| $11.47M+80.5% | $3.08M+34.3% | $6.53M-12.4% | $9.46M+63.2% | $6.35M-10.5% | ||
| $4.35M+2,690% | $4.89M+349% | $2.65M+291% | $1.63M+63.8% | $156K-80.5% | ||
| $6.27M+2.5% | $6.23M+2.5% | $6.19M+2.5% | $6.16M+16.0% | $6.12M+32.3% | ||
| $118.59M+24.7% | $109.57M+9.1% | $116.2M+27.7% | $95.17M+26.1% | $95.07M+30.1% | ||
| $221.22M+1.6% | $220.34M+1.5% | $219.47M+1.5% | $218.63M-5.1% | $217.81M-5.2% | ||
| $31.06M-5.5% | $31.53M-5.2% | $31.99M-4.9% | $32.44M-4.6% | $32.87M-4.4% | ||
| $37.33M-4.3% | $37.76M-4.0% | $38.19M-3.8% | $38.6M-1.8% | $38.99M-0.1% | ||
| $8.13M+68.1% | $8.4M+327% | $3.39M-60.3% | $7.75M+0.5% | $4.83M-20.3% | ||
| $379M+8.1% | $369.84M+4.9% | $371.05M+6.2% | $353.99M+0.8% | $350.58M+1.4% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $18K+12.5% | $17K+13.3% | $17K+13.3% | $16K+6.7% | $16K+6.7% | ||
| $682.09M+5.6% | $685M+6.7% | $681.54M+6.8% | $663.71M+5.1% | $645.96M+3.0% | ||
| -$669.07M+1.8% | -$671.31M+0.1% | -$682.39M-2.3% | -$683.01M-4.9% | -$681.08M-7.1% | ||
| -$24K+4.0% | -$25K0.0% | -$25K-56.3% | -$24K+22.6% | -$25K+30.6% | ||
| $13.01M+137% | $13.69M+146% | -$861K+97.0% | -$19.3M-0.1% | -$35.13M-283% | ||
| $392.01M+24.3% | $383.53M+18.7% | $370.19M+15.3% | $334.69M+0.9% | $315.45M-6.3% | ||
| $5.12M+0.5% | $5.22M-3.5% | $5.32M-2.3% | $5.06M-7.9% | $5.1M+10.5% | ||
| $21.95M-2.6% | $22.11M-2.4% | $22.26M-2.2% | $22.4M-2.0% | $22.53M-2.2% | ||
| $85.37M-11.3% | $88.08M-11.0% | $90.79M-10.7% | $93.5M-10.4% | $96.21M-10.1% | ||
| $21.95M-2.6% | $22.11M-2.4% | $22.26M-2.2% | $22.4M-2.0% | $22.53M-2.2% | ||
| $5.12M+0.5% | $5.22M-3.5% | $5.32M-2.3% | $5.06M-7.9% | $5.1M+10.5% | ||
| $21.95M-2.6% | $22.11M-2.4% | $22.26M-2.2% | $22.4M-2.0% | $22.53M-2.2% | ||
| $5.12M+0.5% | $5.22M-3.5% | $5.32M-2.3% | $5.06M-7.9% | $5.1M+10.5% | ||
| $32.29M+61.0% | $33.16M+19.6% | $30.35M+28.9% | $24.97M+6.3% | $20.05M-10.5% | ||
| $45.49M+48.0% | $43.25M+48.7% | $51.26M+150% | $33.17M+42.5% | $30.73M+36.2% | ||
| $32.29M+61.0% | $33.16M+19.6% | $30.35M+28.9% | $24.97M+6.3% | $20.05M-10.5% | ||
| $18.72M-5.0% | $18.97M-0.6% | $19.22M+8.4% | $19.78M+22.1% | $19.7M+35.0% | ||
| $4.35M+2,690% | $4.89M+349% | $2.65M+291% | $1.63M+63.8% | $156K-80.5% | ||
| $258.55M-3.8% | $258.1M-4.9% | $257.65M-4.9% | $257.22M-4.7% | $268.75M0.0% | ||
| $18K+12.5% | $17K+13.3% | $17K+13.3% | $16K+6.7% | $16K+6.7% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $9.4M+55.8% | $9.55M+28.1% | $11.21M+56.9% | $5.96M-18.9% | $6.03M-21.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Xeris Biopharma Holdings, Inc.'s total assets?
- Xeris Biopharma Holdings, Inc. (XERS) holds $392.0M in total assets, up 24.3% year over year.
- How much debt does Xeris Biopharma Holdings, Inc. have?
- Xeris Biopharma Holdings, Inc. carries $258.6M in total debt against $13.0M of shareholders' equity, a debt-to-equity ratio of 19.87.
- How much cash does Xeris Biopharma Holdings, Inc. have?
- Xeris Biopharma Holdings, Inc. holds $111.8M in cash and equivalents.
- Can Xeris Biopharma Holdings, Inc. cover its short-term obligations?
- Its current ratio is 2.12 — current assets exceed current liabilities.
- Where does Xeris Biopharma Holdings, Inc.'s balance sheet data come from?
- Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
